1

LUMINEX CORPORATION

Patrick J. Balthrop,President and Chief Executive Officer

Harriss T. Currie,Vice President and Chief Financial Officer

4Q and Full Year 2010Results of Operations

February 7, 2011

2

Certain statements made during the course of this presentation may not be purely historical and consequently may be forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to: Statements made regarding our growth initiatives, including new product offerings and new and renewed partner channel relationships, and their ability to create long term shareholder value; our ability to drive growth through innovation; our ability to continue to expand operating margins; prospects for, expected placements of, and expected demand for our MAGPIX instrument; continued expansion of our clinical assay menu; future benefits of our partnership with Advanced Liquid Logic; future effective tax rates and resulting cash payments; future revenues from consumables, royalties and assays as a portion of total revenue mix and future volatility in consumable purchases; future bulk purchases and their effect on the distribution of our total revenue across the 2011 fiscal year; our ability to deliver revenue growth and manage operating costs; future R&D, SG&A and PP&E expenditures; our pipeline of assay and system products, and expected launch dates for assay products; the sustainable level of days sales outstanding; our platform product line strategy, including automation initiatives; driving growth through our indirect partners and international expansion; the macroeconomic environment and expected restraints on capital expenditures; the ability of our products to enhance productivity; distribution of our revenues between the diagnostic and life science research market; the FDA and changes to the 510(k) approval process, and resulting cost increases for Luminex; our revenue guidance and distribution of our revenue over the 2011 fiscal year; overall demand from our end customers; expected instrument placements; future growth rates; the reasonableness of current first quarter street consensus revenue; expectations regarding flu season and revenue contribution from new assay launches; the longer term health of our business and demand for our technology; our strategic outlook and growth plan for our business for 2011 and beyond; our long term financial targets; operational trends, including those related to sales of consumables, royalty revenues and inventory levels; our business outlook and projections about revenues, cash flow, system shipments, expenses and market conditions, and their anticipated impact on Luminex; information regarding development, timing and performance of new products; and, any statements of the plans, strategies and objectives of management for future operations. These forward looking statements speak only as of the date hereof and are based on our current beliefs and expectations and are subject to known or unknown risks and uncertainties some of which are beyond the company’s control that could cause actual results or plans to differ materially and adversely from those anticipated in the forward looking statements. Factors that could cause or contribute to such differences are detailed in our press release or in our annual, quarterly, or other filings with the Securities and Exchange Commission. We undertake no obligation to update these forward looking statements.

Also, certain non-GAAP financial measures as defined by SEC Regulation G, may be covered in this presentation. To the extent that any non-GAAP financial measures are covered, a presentation of and reconciliation to the most directly comparable GAAP financial measures will be included in this presentation and/or be available on our website at www.luminexcorp.com in accordance with Regulation G.

Safe Harbor

3

4Q and 2010 Highlights

4Q and 2010 Financial Review

2011 Outlook and Guidance

Q&A

Today’s Agenda

4

Record consolidated revenue of $41.2M, +8% Y/Y Key revenue segments:

Consumable revenue of $12.0M, +49%Royalty revenue of $6.0M, +26%Assay revenue of $9.2M, -28% (H1N1 boost in 4Q09)System revenue of $10.3M, +11%

286 multiplexing analyzers, incl. 16 FLEXMAP 3D and 34 MAGPIX units

Consolidated gross margin of 69.4%, +220bps Y/YOperating income of 12.4% of consolidated revenue Net income of $3.2M, or $0.07 per fully diluted share

4Q 2010 Financial Highlights

5

FDA Clearance of RVP

5000th instrument shipped

Launch FLEXMAP 3D®

SG&A Management

Strategic Partnerships

Executing on the Growth Plan

Investment in R&D +55% Y/Y

LBG investment, launch of two assays

Investment in Infrastructure, Reg, Mktg, Service

Investment in R&D +77% Y/Y

Tm Acquisition Closed

Announce Next Gen Instrument: FLEXMAP 3D®

Launch xTAG® RVP

Launch FlexmiR®

Select miRNA

-3%

-1%

1%

3%

5%

7%

9%

2006 2007 2008 2009 2010

$0

$20

$40

$60$80

$100

$120

$140

2006 2007 2008 2009 2010

2007 2008 20092006

Revenue ($M) Margins (%)

Rollout of RVP Package Insert- H1N1

LMNX Shanghai

LMNX Tokyo

New CF w/ ‘Fast Chemistry’

RVP Awareness Campaign

2010Launch of MAGPIX ®

Renew OLI agreement

Launch of qBead

7000th instrument shipped

BSD Robotics acquisition

ALL and HTG agreements

-23%*

CAGR = 28%68% 67% 68% 67% 68%

OMGM

* 2007 not to scale

6

Operational Accomplishments:Developed and successfully launched MAGPIX®

Acquired and fully integrated BSD Robotics

Renewed partnership with leader in the HLA testing market, One Lambda

Received FDA clearance for assays: CYP450 2D6, CF-60 V2

Advanced with Biothreat programs

Strategic Initiatives:Signed exclusive collaboration/license agreement with Advanced Liquid Logic

HTG Partnership – Custom gene expression assay (qBead)

Tecan partnership for high volume automation

2010 Corporate Highlights

7

4Q and 2010 Highlights

4Q and 2010 Financial Review

2011 Outlook and Guidance

Q&A

8

Q4 and 2010 Income Statement

* The income tax adjustment of $15.7M in the fourth quarter of 2009 and $19.0M for the full year 2009 reflects the amount of additional tax expense that would have been recorded had the valuation allowance been released prior to 2009 and the U.S. income was shown as if fully taxed.

The Company believes that the non-GAAP measure used in this presentation, when presented in conjunction with the comparable GAAP measure, is useful to both management and investors in analyzing financial and business trends regarding the Company's ongoing business and operating performance. This non-GAAP measure should be considered in addition to, but not as a substitute for, items prepared in accordance with GAAP.

4Q 2010 4Q 2009 Variance 2010 2009 Variance

Revenue 41,190$ 38,167$ 3,023$ 141,557$ 120,643$ 20,914$

Gross Margin % 69% 67% 2% 68% 67% 1%

Operating Expenses 23,496 20,357 (3,139) 85,126 73,895 (11,231)

Operating Profit 5,083 5,298 (215) 11,251 7,399 3,852

Operating Profit % 12% 14% -2% 8% 6% 2%

Net Income: As Reported 3,199$ 20,016$ (16,817)$ 5,231$ 17,729$ (12,498)$

Income Tax Adjustment* - (15,707) 15,707 - (19,004) 19,004

Adjusted Net Income (Loss) 3,199$ 4,309$ (1,110)$ 5,231$ (1,275)$ 6,506$

EPS, As Reported (Basic) 0.08$ 0.49$ (0.41)$ 0.13$ 0.44$ (0.31)$

EPS, Adjusted (Basic) 0.08$ 0.11$ (0.03)$ 0.13$ (0.03)$ 0.16$

($ in thousands - except per share amounts)

9

Q4 and 2010 Segment Results4Q 2010 4Q 2009 Variance 2010 2009 Variance

RevenueTechnology &Strategic Partnerships 30,550$ 24,794$ 5,756$ 105,586$ 87,389$ 18,197$

Assays &Related Products 10,640 13,373 (2,733) 35,971 33,254 2,717

Total Revenue 41,190 38,167 3,023 141,557 120,643 20,914

Operating Income (Loss)Technology &Strategic Partnerships 5,872 2,669 3,203 15,977 8,122 7,855

Assays &Related Products (789) 2,629 (3,418) (4,726) (723) (4,003)

Total Operating Income 5,083$ 5,298$ (215)$ 11,251$ 7,399$ 3,852$

Total Operating Margin 12% 14% -2% 8% 6% 2%

($ in thousands)

10

$0

$20,000

$40,000

$60,000

$80,000

$100,000

$120,000

$140,000

2010 2009$0

$5,000$10,000$15,000$20,000$25,000$30,000$35,000$40,000$45,000

Q4 2010 Q4 2009

66% 67%

System Revenue Consumable RevenueRoyalty Revenue Assay RevenueService Revenue Other Revenue

67%64%

Consolidated Revenue Distribution($ in thousands) ($ in thousands)

11

Bulk Consumables

$0

$2,000

$4,000

$6,000

$8,000

$10,000

$12,000

08-Q4 09-Q1 09-Q2 09-Q3 09-Q4 10-Q1 10-Q2 10-Q3 10-Q4

($ in thousands)

Non-bulk Bulk 4 Qtr MA

Bulk purchases of consumables account for the majority of the volatility

84%

12

$10

$13

$16

$19

$22

$25

2007 2008 2009 201042%

43%

44%

45%

46%

47%

2007 2008 2009 2010

Management focus on driving operating leverage, particularly from the G&A portion

SG&A (% of Total Revenue) Research and Development ($M)

Potential for Operating Leverage

Focus on driving long term growth through significant continued investment in R&D

CAGR = 17%

20% 18% 17% 17% % of Rev

13

Focused on delivering results in 2010Focused on delivering results in 2010

Consolidated TSP and ARP Operations

Long-term Compounded Annual Revenue Growth of 20+ Percent

All Metrics Except Revenue Growth Expressed in Percent of Current Year Revenue

*Adjusted for the settlement of litigation

Metric 2007 2008 2009 2010 Long TermTargets

Revenue 100% 100% 100% 100%

Revenue Growth (YoY) 42% 39% 16% 17% 20+%

Gross Profit 61% 68% 67% 68% 65% - 75%

R&D Expense 21% 18% 17% 17% 15%

Pretax Income (Loss) (3)% 4% 6%* 8% 25% - 35%

Long Term Financial Targets

14

Strong Balance Sheet($ in millions) 12/31/2010 09/30/2010 12/31/2009

Cash & Investments 123.9$ 118.3$ 119.6$

Accounts Receivable 20.9$ 19.0$ 22.1$

DSO 47 52 53

Inventory 24.9$ 24.1$ 17.5$

Inventory Turns 0.5 0.5 0.8

Total Assets 265.8$ 259.0$ 248.0$

Current Ratio 8.7 8.6 7.2

Days Payable 56 53 62

15

110

115

120

125

130

135

140

145

Cash & Investments12/31/09

Operating Cash Flow PP&E Purchases StrategicInvestments

Equity Issuances Other Items Cash & Investments12/31/10

($ in millions)

Cash & Investment Flow

119.6M

24.2M 11.1M

8.3M

2.2M 2.7M

123.9M

16

4Q and 2010 Highlights

4Q and 2010 Financial Review

2011 Outlook and Guidance

Q&A

17

Platforms / Product Line StrategyMAGPIX®

Automation InitiativesBSD Robotics, ALL, Tecan

Assay LaunchesRVP FastGastrointestinal Pathogen Panel – CE MarkNewborn Screening / NeoPlex 4™ - CE MarkMeningitis - CE Mark

Specialty MarketsBiothreat program

International Expansion

2011 Outlook – Growth Drivers

18

Stable cap-ex across key markets/customersEU – FY11 funding stable at core membersUS – House proposed flat FY11 NIH budget Y/Y Asia – Japan +3%, strong growth in China

Luminex has limited exposure to LSR CapexLSR systems account <20% of total revenue

Regulatory environment is challengingImproving clarity on 510(k) process in 2011 Still plan for the FDA to require more data per 510(k) submission, higher costs per clinical study

2011 Outlook - Macro Environment

19

2011 Guidance2011 revenue of $163M - $170M or up to 20% growth Y/Y

100 110 120 130 140 150 160 170 180

2009

2010

2011

$MActual Lower End of 2011 Guidance Upper End of 2011 Guidance

Revenue Segment

Systems

Consumables

Royalties

Assays

Lower End of Range Upper End of Range

Very strong demand for MAGPIX®

Strong partner expansion of development activities

Expansion of partner assay menu; high market demand

Higher contribution from new products, normal ILI season

Strong demand for MAGPIX®

Consistent partner utilization

Moderate contribution from new products, light ILI season

Continued growth

20

4Q and 2010 Highlights

4Q and 2010 Financial Review

2011 Outlook and Guidance

Q&A

21

LUMINEX CORPORATION

Patrick J. Balthrop,President and Chief Executive Officer

Harriss T. Currie,Vice President and Chief Financial Officer

4Q and Full Year 2010Results of Operations

February 7, 2011